drugset
Drugs / WT1 126-134 peptide vaccine
last change Mar 2018 re-read 2 minutes ago

WT1 126-134 peptide vaccine

Vaccine targets WT1

Developed for
acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, del(5q31-q32) · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(15;17)(q24;q21) · acute myeloid leukemia, t(16;16)(p13.1;q22)
Investigated by
National Cancer Institute (NCI) · University of Chicago

Trials 1 · a red edge is where a trial was stopped

today NCT01842139 · Ph 1
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01842139 Dec 2011 → Feb 2015 acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32), acute myeloid leukemia, inv(16)(p13.1;q22) +2 University of Chicago Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as WT1 126-134 peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01842139 ↗
Modality Vaccine “WT1 peptide vaccine with Montanide as an adjuvant” PMID 29344432 ↗ Jan 2018
Route Subcutaneous “subcutaneously (SC) on day 0 and then once every 2 weeks” NCT01842139 ↗
Target WT1 “WT1-specific immune response” PMID 29344432 ↗ Jan 2018